Memorial Sloan Kettering Cancer Center investigators report that T cell interferon-γ (IFNγ) orchestrates a dendritic-cell–natural-killer-cell circuit that suppresses leptomeningeal metastases in mouse ...

B-cell acute lymphoblastic leukemia (B-ALL) is the most common cancer in children, accounting for around 85% of pediatric ...

An international clinical trial shows an innovative CAR-T cell immunotherapy is promising against aggressive T cell cancers and has manageable side effects.

Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced ...

MS patients on B-cell depleting therapies are still protected against COVID-19 risk due to greater anti-viral T-cell activity, a study found.

This study identifies 53BP1 as an interaction partner of GMCL1 (a likely CUL3 substrate receptor). The study seeks to link this finding to regulation of the mitotic surveillance pathway and paclitaxel ...

The findings suggest assessment of CD20 may be an important factor in determining treatment options in B-cell lymphomas.

On May 25th, 2020, the Minneapolis Police Department released a statement saying “Man Dies After Medical Incident During Police Interaction”. The man in question was George Floyd and he was murdered ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. A next-generation "armored" CAR T cell therapy ...

Study in mice shows how a host-elicited factor benefits gut immunological homeostasis by selectively targeting commensal ceramide molecules.